CG Oncology, Inc.
CGON evidence brief
What we can confirm
- BioSniper Score:
- 5.4 / 10
- Market Cap:
- $6.51B
- Next Catalyst:
- Phase2_Start · Dec 18, 2026
What it means
What to watch
Prepared research question
What matters most for CGON—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CGON
CG Oncology is a late-stage biopharmaceutical company developing cretostimogene, an oncolytic immunotherapy for bladder cancer, with a BLA submission expected in Q4 2026.
Key risk: No approved products
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 133 clinical trials · 2 catalysts for CG Oncology, Inc..
CG Oncology is a late-stage biopharmaceutical company developing cretostimogene, an oncolytic immunotherapy for bladder cancer, with a BLA submission expected in Q4 2026.
- CG Oncology is focused on cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy with a dual mechanism of action [sec_mda · as of 2026-08-06].
- Reported a 75.5% complete response (CR) at any time in a monotherapy trial, with 12- and 24-month duration of response rates of 64.2% and 60.1%, respectively [sec_mda · as of 2026-08-06].
- Expects to complete its Biologics License Application (BLA) submission to the FDA in the fourth quarter of 2026 [sec_mda · as of 2026-08-06].
- Cash and equivalents of $19.6M as of 2026-06-30, with aggregate gross proceeds of approximately $1,532.9M from stock sales through June 30, 2026 [sec_mda · as of 2026-08-06].
- Cretostimogene has received both Fast Track and Breakthrough Therapy designations from the FDA [sec_mda · as of 2026-08-06].
What works
- Cretostimogene has demonstrated potentially best-in-disease efficacy with a 75.5% complete response rate and durable responses in a Phase 2 trial [sec_mda · as of 2026-08-06].
- The company has a clear near-term catalyst: a BLA submission expected in Q4 2026, supported by Fast Track and Breakthrough Therapy designations [sec_mda · as of 2026-08-06].
- CG Oncology has raised substantial capital, with aggregate gross proceeds of approximately $1,532.9 million from stock sales through June 30, 2026 [sec_mda · as of 2026-08-06].
What to weigh
- The company has no approved products and does not expect revenue from product sales for several years, if ever [sec_mda · as of 2026-08-06].
- Net income was -$79.1M for the period ending 2026-06-30, reflecting ongoing operating losses [sec].
- Cash and equivalents stood at only $19.6M as of 2026-06-30, which may be insufficient if operating costs exceed projections [sec].
- The company faces a competitive landscape with at least 25 competitors in the non-muscle invasive bladder cancer space [pipeline].
From the filings
Quoted directly from source documents.
Cretostimogene achieved a 75.5% complete response rate in a monotherapy trial.
“These results included a 75.5% complete response (CR) at any time, after receiving cretostimogene as monotherapy”
SEC MD&A · August 6, 2026
BLA submission is expected in Q4 2026.
“we expect to complete in the fourth quarter of 2026”
SEC MD&A · August 6, 2026
Cretostimogene has Fast Track and Breakthrough Therapy designations.
“Cretostimogene has received both Fast Track and Breakthrough Therapy designations from the FDA”
SEC MD&A · August 6, 2026
Cash and equivalents as of June 30, 2026.
“As of June 30, 2026, we had cash, cash equivalents and”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2026-12-18 · Phase2_Start: A Phase II Randomized Study of Reirradiation for Locally Recurrent Non-Small Cell Lung Cancer — Initiation of a Phase 2 trial for reirradiation in recurrent NSCLC.
- 2027-01-28 · Phase3_Start: A Randomized Phase 3 Clinical Trial of Postoperative Radiotherapy Versus Postoperative Surveillance for Clinical Low-Risk, Molecular High-Risk Meningioma and Longitudinal Surveillance for Clinical and Molecular Low-Risk Meningioma — Initiation of a Phase 3 trial comparing postoperative radiotherapy to surveillance in meningioma.
Risks & what to watch (4)›
Key risks
- No approved products — No revenue from product sales until regulatory approval, which may never occur [sec_mda · as of 2026-08-06].
- Limited cash runway — Cash and equivalents of $19.6M as of 2026-06-30 may be insufficient if operating costs exceed projections [sec].
- Intense competition — At least 25 competitors in the non-muscle invasive bladder cancer space [pipeline].
- Operating losses — Net income of -$79.1M for the period ending 2026-06-30 [sec].
What to watch
- Completion of BLA submission to the FDA in Q4 2026 [sec_mda · as of 2026-08-06].
- FDA decision on Breakthrough Therapy designation for cretostimogene [sec_mda · as of 2026-08-06].
- Cash position updates and any additional financing rounds [sec_mda · as of 2026-08-06].
- Phase 2 data from ongoing trials in intermediate-risk NMIBC [sec_mda · as of 2026-08-06].
Sources: Catalysts · News · Pipeline · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run CG Oncology, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CG Oncology, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Pipeline inputs are unavailable for this score. It uses only the available signals shown below.
Cash runway data unavailable
D/E 0.05 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
2 upcoming, next in ~65d
1 buy · 9 sells (180d)
Catalysts
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 10.7%
- Days to cover
- 8.2
- Shares short
- 9,222,491
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CGON short interestGovernance
Frequently asked questions
What is the AI investment thesis for CG Oncology, Inc.?
CG Oncology is a late-stage biopharmaceutical company developing cretostimogene, an oncolytic immunotherapy for bladder cancer, with a BLA submission expected in Q4 2026.
What is CG Oncology, Inc.'s next catalyst?
CG Oncology, Inc.'s next tracked catalyst is a Phase2_Start event — "Phase2_Start: A Phase II Randomized Study of Reirradiation for Locally Recurrent Non-Small Cell Lung Cancer" — expected December 18, 2026.
Who is the CEO of CG Oncology, Inc.?
Mr. Arthur Kuan is the chief executive officer of CG Oncology, Inc. (CGON).
Where is CG Oncology, Inc. headquartered?
CG Oncology, Inc. (CGON) is headquartered in Dallas, TX, United States.
What therapeutic areas does CG Oncology, Inc. focus on?
CG Oncology, Inc. develops therapies across Oncology, Gene Therapy, Neurology, Immunology, Infectious Disease, Dermatology, Hematology, Nephrology, Musculoskeletal, Gastroenterology, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.